Vaxcyte

Nasdaq:  PCVX

Filing Date:  05/22/20

Launch Date:  06/08/20

Price Range:  $14.00 - $16.00

Shares Offered (Pre-Shoe, mm):  14.0

Primary Shares (mm):  14.0

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $210.0

% Secondary:  0.0%

Shares Outstanding (mm):  46.8

Market Value at IPO Midpoint (mm):  $701.4

Offering as % of Market Value:  29.9%

Bookrunners:  Bank of America | Jefferies | Evercore

Co-Managers:  Cantor | Needham

Major Holders:  Abingworth Bioventures | Longitude Capital Partners | Roche | TPG | Frazier Life Sciences | Pivotal bioVentures | Sutro Biopharma | Medicxi Ventures | Janus Henderson | RA Capital Management

Description:  Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Note:  Emerging Growth Company

Reference Link:  S-1/A